Delivering LSD via microneedle patch unlocks potential for desired dosage forms and pharmacokinetic profiles for improved safety and effectiveness Pursuing Phase 2 clinical studies in 2022 with LSD and notable psychedelics TORONTO, Dec. 14, 2021 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company…


Previous articlePT277 – Ryan Zurrer – Venture Capital, Reciprocity, and the Regenerative Financing Vine
Next articleEditor’s Choice Award 2021-Best Study on Psychedelics and Neuroplasticity